Nikolaj Sorensen - Orexo AB Pres CEO
| ORX Stock | SEK 9.55 0.15 1.60% |
CEO
Mr. Nikolaj Sorensen has served as President and Chief Executive Officer of Orexo AB since February 5, 2013. He joined the Company in 2011 and was appointed Chief Commercial Officer on October 1, 2011 since 2013.
| Age | 51 |
| Tenure | 11 years |
| Phone | 46 1 87 80 88 00 |
| Web | https://www.orexo.com |
Orexo AB Management Efficiency
The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Fredrik Tiberg | Camurus AB | 60 | |
| Martin Welschof | BioInvent International AB | 62 | |
Management Performance
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 |
Orexo AB Leadership Team
Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fredrik Jarrsten, Ex CFO | ||
| MD MBA, Chief Officer | ||
| Cecilia Coupland, Vice President and Head of Operations | ||
| Nikolaj Sorensen, Pres CEO | ||
| Lena Wange, Investor Relations & Communications Manager | ||
| Jesper Lind, Advisor | ||
| Dennis Urbaniak, Ex Therapeutics | ||
| Robert DeLuca, President of Orexo US Inc. | ||
| Robert Ronn, Vice President and Head of Research & Development |
Orexo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Operating Margin | (0.29) % | |||
| Current Valuation | 795.36 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 17.29 % | |||
| Shares Owned By Institutions | 42.78 % | |||
| Price To Earning | 14.08 X | |||
| Price To Book | 2.34 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Orexo Stock Analysis
When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.